Kenneth Galbraith, Zymeworks CEO
June 6, 2022 09:00 AM EDTUpdated 11:49 AM
R&D

#AS­CO22: As it dodges a takeover bid, Zymeworks wants what Dai­ichi Sankyo got: a mas­sive Big Phar­ma part­ner

Kyle LaHucik

Senior Reporter

CHICA­GO — The Dai­ichi Sankyo sto­ry made waves Sun­day at the an­nu­al AS­CO meet­ing in Chica­go, as En­her­tu po­ten­tial­ly dis­rupt­ed the breast can­cer land­scape by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times